



Substitute for form 1449A/PTO (Modified)		Complete if Known			
		Application Number	09/454,481		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 3, 1999		
		First Named Inventor	ALLISON, James P.		
		Art Unit	1642		
		Examiner Name	Rawlings, S.L.		
Sheet	1	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SR	A1	5,434,131	07-18-1995	Linsley et al.	
	A2	5,770,197	06-23-1998	Linsley et al.	
	A3	5,773,253	06-30-1998	Linsley et al.	
	A4	5,844,095	12-01-1998	Linsley et al.	
	A5	5,851,795	12-22-1998	Linsley et al.	
	A6	5,869,057	02-09-1999	Rock	
	A7	5,885,796	03-23-1999	Linsley et al.	
	A8	5,968,510	10-19-1999	Linsley et al.	
	A9	5,977,318	11-02-1999	Linsley et al.	
	A10	6,090,914	07-18-2000	Linsley et al.	
	A11	6,323,027 B1	11-27-2001	Burkly et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
SR	B1	WO 95/01994 A1	01-19-1995	Synergen, Inc.		
	B2	WO 95/34320 A2	12-22-1995	Regents of the University of Minnesota		
	B3	WO 96/14865 A1	05-23-1996	Repligen Corp.		
	B4	WO 00/32231 A1	06-08-2000	The Regents of the University of California		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁵
SR	C1	ALLISON, J.P., et al., "The yin and yang of T cell co-stimulation," <i>Science</i> 270(5238):932-933 (Nov. 1995).			
↓	C2	BELLDEGRUN, A., et al., "Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity," <i>Cancer Res.</i> Jan. 1988, 481:206-214.			
	C3	BLUESTONE, J.A., "New perspectives of CD28-B7-mediated T cell costimulation," <i>Immunity</i> 2(6):555-559 (Jun. 1995).			
	C4	BRUNET, J.-F., et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> 328(6127):267-270 (Jul. 1987).			
↓	C5	CHAUDHARY, J., et al., "Caloxin: a novel plasma membrane Ca ²⁺ pump inhibitor," <i>Am. J. Physiol. Cell Physiol.</i> 280(4):C1027-C1030 (Apr. 2001).			

Examiner Signature		Date Considered	6/25/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/454,481		
		Filing Date	December 3, 1999		
		First Named Inventor	ALLISON, James P.		
		Art Unit	1642		
		Examiner Name	Rawlings, S.L.		
Sheet	2	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	C6	CHEN, L., et al., "Costimulation of antitumor activity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," <i>Cell</i> 71(7):1093-1102 (Dec. 1992).	
	C7	DAMLE, N., et al., "Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7," <i>J. Immunol.</i> 152(6):2686-2697 (Mar. 1994).	
	C8	DARIAVACH, P., et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> 18(12):1901-1905 (Dec. 1988).	
	C9	De WAAL MALEYFYT, R., et al., "CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 23(2):418-424 (Feb. 1993).	
	C10	DeVITA, V., "The relationship between tumor mass and resistance to chemotherapy," <i>Cancer</i> 51(7):1209-1220 (Apr. 1983).	
	C11 *	DEVLIN, J., et al., "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> 249(4967):404-406 (Jul. 1990).	
	C12	FREEMAN, G.J., et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," <i>Science</i> 262(5135):907-909 (Nov. 1993).	
	C13 *	GOODSON, R., et al., "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," <i>Proc. Natl. Acad. Sci. USA</i> 91(15):7129-7133 (Jul. 1994).	
	C14 *	GRIBBEN, J., et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci. USA</i> 92(3):811-815 (Jan. 1995).	
	C15	GROSS, J., et al., "Identification and distribution of the costimulatory receptor CD28 in the mouse," <i>J. Immunol.</i> 149(2):380-388 (Jul. 1992).	
	C16	GROSS, J., et al., "The murine homologue of the T lymphocyte antigen CD28," <i>J. Immunol.</i> 144(8):3201-3210 (Apr. 1990).	
	C17	HARDING, F., et al., "CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help," <i>J. Exp. Med.</i> 177(6):1791-1796 (Jun. 1993).	
	C18	HARDING, F., et al., "CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> 356(6370):607-609 (Apr. 1992).	
	C19	HARPER, K., et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J. Immunol.</i> 147(5):1037-1044 (Aug. 1991).	
	C20 *	HODI, J.S., et al., "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients," <i>Proc. Natl. Acad. Sci. USA</i> 100(8):4712-4717 (Apr. 2003).	
	C21	HUANG, Y.W., et al., "Immunotherapy of multiple myeloma," <i>Stem Cells</i> 13(2):123-134 (Mar. 1995).	
	C22	JENKINS, M., et al., "T-cell unresponsiveness <i>in vivo</i> and <i>in vitro</i> : fine specificity induction and molecular characterization of the unresponsive state," <i>Immunol. Rev.</i> 95():113-135 (Feb. 1987).	

Examiner Signature		Date Considered	6/25/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/454,481		
		Filing Date	December 3, 1999		
		First Named Inventor	ALLISON, James P.		
		Art Unit	1642		
		Examiner Name	Rawlings, S.L.		
Sheet	3	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	P ⁶
se	C23	JENKINS, M.K., "The ups and downs of T cell activation," <i>Immunity</i> 1(6):444-446 (Sep. 1994).	
	C24	JUNE, C.H., et al., "The B7 and CD28 receptor families," <i>Immunol. Today</i> 15(7):321-331 (Jul. 1994).	
	C25	JUNE, C.H., et al., "Role of the CD28 receptor in T-cell activation," <i>Immunol. Today</i> 11(6):211-216 (Jun. 1990).	
	C26	KRUMMEL, M., et al., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J. Exp. Med.</i> 182(2):459-465 (Aug. 1995).	
	C27	KWON, E., et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94(15):8099-8103 (Jul. 1997).	
	C28	LANE, P., et al., "Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human $\gamma 1$," <i>Immunology</i> 80(1):56-61 (Sep. 1993).	
	C29	LENSCHOW, D.J., et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc. Natl. Acad. Sci. USA</i> 90(23):11054-11058 (Dec. 1993).	
	C30	LENSCHOW, D.J., et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> 257(5071):789-792 (Aug. 1992).	
	C31	LIN, H., et al., "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4lg plus donor-specific transfusion," <i>J. Exp. Med.</i> 178(5):1801-1806 (Nov. 1993).	
	C32	LINDSTEN, T., et al., "Characterization of CTLA-4 structure and expression on human cells," <i>J. Immunol.</i> 151(7):3489-3499 (Oct. 1993).	
	C33	LINSLEY, P., et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J. Exp. Med.</i> 176(6):1595-1604 (Dec. 1992).	
	C34	LINSLEY, P., et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> 174(3):561-569 (Sep. 1991).	
	C35	LINSLEY, P., et al., "Distinct roles for CD28 and cytotoxic lymphocyte-associated molecule-4 receptors during T cell activation," <i>J. Exp. Med.</i> 182(2):282-285 (Aug. 1995).	
	C36	LINSLEY, P., et al., "Immunosuppressive in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> 257(5071):792-795 (Aug. 1992).	
	C37	LINSLEY, P., et al., "Lymphocyte activation: T-cell regulation by CTLA-4," <i>Curr. Biol.</i> 6(4):398-400 (Apr. 1996).	
	C38	LINSLEY, P., et al., "The role of the CD28 receptor during T cell responses to antigen," <i>Annu. Rev. Immunol.</i> 11():191-212 (1993).	
	C39	NELSON, A.J., et al., "Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro," <i>J. Immunol.</i> 151(5):2453-2461 (Sep. 1993).	
	C40 *	OLDENBURG, K., et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library," <i>Proc. Natl. Acad. Sci. USA</i> 89(12):5393-5397 (Jun. 1992).	
✓	C41	PEACH, R., et al., "Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1," <i>J. Exp. Med.</i> 180(6):2049-2058 (Dec. 1994).	

Examiner Signature		Date Considered	6/25/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified)		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/454,481		
		Filing Date	December 3, 1999		
		First Named Inventor	ALLISON, James P.		
		Art Unit	1642		
		Examiner Name	Rawlings, S.L.		
Sheet	4	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SE	C42 *	PHAN, G.Q., et al., "Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma," <i>Proc. Natl. Acad. Sci. USA</i> 100(14):8372-8377 (Jul. 2003).	
	C43	ROSENBERG, S., et al., "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone," <i>New Engl. J. Med.</i> 316(15):891-897 (Apr. 1987).	
	C44	ROSENTHAL, F., et al., "Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity," <i>Curr. Opin. Oncol.</i> 6(6):611-615 (Nov. 1994).	
	C45	SCHWARTZ, R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> 71(7):1065-1068 (Dec. 1992).	
	C46 *	SPARKS, A., et al., "Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries," <i>J. Biol. Chem.</i> 269(39):23853-23856 (Sep. 1994).	
	C47	TJOA, B., et al., "Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection," <i>Cancer Res.</i> 54(1):204-208 (Jan. 1994).	
	C48	TOWNSEND, S., et al., "Specificity and longevity of antitumor immune responses induced by B7-transfected tumors," <i>Cancer Res.</i> 54(24):6477-6483 (Dec. 1994).	
	C49	TRAVIS, J., "A stimulating new approach to cancer treatment," <i>Science</i> 259(5093):310-311 (Jan. 1993).	
	C50	TURKA, L., et al., "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 89(22):11102-11105 (Nov. 1992).	
	C51	VAN ELSAS, A., et al., "Blockade of CTLA-4 cinvubed wutg a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces depigmentation," <i>FASEB J.</i> 12(5):A908 (Mar. 1998) (Abstract #5258).	
	C52	VAN ELSAS, A., et al., "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation," <i>J. Exp. Med.</i> 190(3):355-366 (Aug. 1999).	
	C53	VAN SEVENTER, G., et al., "Roles of multiple accessory molecules in T-cell activation," <i>Curr. Opin. Immunol.</i> 3(3):294-303 (Jun. 1991).	
	C54	WATERHOUSE, P., et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> 270(5238):985-988 (Nov. 1995).	
	C55	WELLS, A., et al., "Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy," <i>J. Clin. Invest.</i> 108(6):895-903 (Sep. 2001).	
	C56	WOODLE, E.S., et al., "In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells," <i>Transplantation</i> 61(5):798-803 (Mar. 1996).	
	C57	WU, Y., et al., "CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion," <i>J. Exp. Med.</i> 185(7):1327-1335 (Apr. 1997).	
	C58 *	XU, H., et al., "A novel PCNA-binding motif identified by the panning of a random peptide display library," <i>Biochemistry</i> 40(14):4512-4520 (Apr. 2001).	

Examiner Signature		Date Considered	6/28/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial-number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/454,481
				Filing Date	December 3, 1999
				First Named Inventor	ALLISON, James P.
				Art Unit	1642
				Examiner Name	Rawlings, S.L.
Sheet	5	of	5	Attorney Docket Number	A-68668/RFT/TAL/CYO (465174-00312)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ⁶
SR	C59 *	YANOFSKY, S., et al., "High affinity type I interleukin 1 receptor antagonists discovered by screenin grecombinant peptide libraries," <i>Proc. Natl. Acad. Sci. USA</i> 93(14):7381-7386 (Jul. 1996).	—

Examiner Signature		Date Considered	6/25/04
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2